Drugmakers Commit to Reducing Drug Launch Times in the EU

Members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) have pledged to file for pricing and reimbursement in all EU countries as early as possible in order to reduce the launch time of new therapeutics. The drugmakers aim to make filings within two years of EU market approval. This move would help standardize a widely disparate range of launch times across the EU.

According to Phil Taylor of PharmaPhorum, ” The move is in response to IQVIA data published by EFPIA last week that revealed stark differences in the time it takes to access new medicines across EU member states, ranging from an average of around 133 days in Germany to around 900 days – almost two and a half years – in Romania. There’s something of an east-west divide as well. Less than 30% of centrally-approved products are available in smaller and east European countries, compared with 92% in Germany and 46% on average across all 27 countries in the EU.”

Read more by clicking here.

(Source: PharmaPhorum, April 11^th, 2022)